Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunities

Eur Heart J. 2021 Feb 11;42(6):697-699. doi: 10.1093/eurheartj/ehaa765.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Aging
  • Fibrosis
  • Heart Failure* / drug therapy
  • Humans
  • Mineralocorticoid Receptor Antagonists* / therapeutic use
  • Spironolactone
  • ras Proteins

Substances

  • MRAS protein, human
  • Mineralocorticoid Receptor Antagonists
  • Spironolactone
  • ras Proteins